AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32451120
Drug: Efavirenz 800
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 800 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GG genotype
Trial: 32451120
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GT genotype
Trial: 32451120
Drug: Efavirenz 200
RxNorm normalized name: efavirenz 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 200 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 TT genotype
Trial: 32451120
Drug: Rifampicin co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin co-administration
Trial: 32451615
Drug: Daclizumab beta
RxNorm normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years
Trial: 32451615
Drug: Daclizumab beta
RxNorm normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab beta treatment
Trial: 32452555
Drug: Promoting the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promoting the administration of antenatal corticosteroids (ACS)
Trial: 32453640
Drug: DA-EPOCH-R therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-EPOCH-R therapy (3 cycles for low-risk, 6 cycles with CNS prophylaxis for high-risk)
Trial: 32453841
Drug: Anti-CD19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19 CAR T-cell therapy
Trial: 32453841
Drug: Allogeneic hematopoietic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic hematopoietic stem cell transplant (allo-HSCT) after CAR T-cell therapy
Trial: 32458180
Drug: Overall patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall patient satisfaction with ablation therapy
Trial: 32458378
Drug: Vericiguat co-administered
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vericiguat co-administered with various drugs (omeprazole, magnesium/aluminum hydroxide, ketoconazole, rifampicin, mefenamic acid, midazolam, warfarin, digoxin, sacubitril/valsartan, aspirin, sildenafil)
Trial: 32459419
Drug: Recreational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational drug use before pregnancy (33.8%) vs during pregnancy (1.1% at visit 2, 0.7% at visit 3, 0.4% at visit 4)
Trial: 32459639
Drug: Wearable blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable blood pressure monitoring device (Health Gauge), daily self-monitoring of blood pressure and monthly evaluation for weight gain from 20 weeks of gestation until delivery
Trial: 32459957
Drug: MEDI3726 (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3726 (an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate)
Trial: 32460197
Drug: Crizotinib treatment
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib treatment
Trial: 32461262
Drug: 0.2 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 µg/day fluocinolone acetonide (FAc) implant
Trial: 32463152
Drug: Cabozantinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (100 mg/day, later reduced to 60 mg/day)
Trial: 32464183
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with obesity and insulin resistance
Trial: 32464281
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg/day for 1 year plus loperamide prophylaxis (days 1-28)
Trial: 32464281
Drug: Neratinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib dose escalation (DE)
Trial: 32464282
Drug: R-CODOX-M/R-IVAC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CODOX-M/R-IVAC chemotherapy (alternating cycles of CODOX-M and IVAC plus eight doses of rituximab)
Trial: 32464282
Drug: R-CODOX-M/R-IVAC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CODOX-M/R-IVAC chemotherapy
Trial: 32464368
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (sRT) with hormonal therapy
Trial: 32464368
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (sRT) without hormonal therapy
Trial: 32466779
Drug: First-line aromatase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line aromatase inhibitor (AI) treatment
Trial: 32467323
Drug: Alteplase 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 0.9 mg/kg intravenously
Trial: 32467765
Drug: Anti-IL5/IL5R therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL5/IL5R therapy
Trial: 32467765
Drug: Anti-IgE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IgE therapy
Trial: 32467765
Drug: Biological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological therapy (general)
Trial: 32468741
Drug: Vorico® Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorico® Injection (test formulation)
Trial: 32468741
Drug: Vfend® IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vfend® IV (reference formulation)
Trial: 32469092
Drug: Dupilumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab as add-on therapy to maximal standard of care
Trial: 32469129
Drug: Wearable fitness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable fitness device (Garmin Vivoactive HR) and exercise prescription (150 min of moderately to vigorous exercise per week)
Trial: 32469185
Drug: Tepotinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib (500 mg once daily)
Trial: 32469386
Drug: FOLFIRINOX (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX (fluorouracil 400 mg/m2 bolus, 2400 mg/m2 over 46 hours; leucovorin 400 mg/m2; irinotecan 180 mg/m2; oxaliplatin 85 mg/m2) with trastuzumab for ERBB2-positive patients (6 mg/kg loading dose, then 4 mg/kg every 14 days)
Trial: 37290461
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg orally once daily)
Trial: 32471030
Drug: Nivolumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (12 patients), combination of nivolumab and ipilimumab (1 patient), pembrolizumab (remaining patients)
Trial: 32471909
Drug: Hyperglycemic condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic condition (second scanning session, 20 mmol/L [360 mg/dL])
Trial: 32471990
Drug: Targeted fusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted fusion therapies
Trial: 32472007
Drug: Standardised frankincense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised frankincense extract (SFE) taken daily for eight months
Trial: 32472319
Drug: CDX-014 administered
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDX-014 administered intravenously at doses ranging from 0.15 to 2.0 mg/kg every 2 or 3 weeks until progression or unacceptable toxicity.
Trial: 32474892
Drug: JE-CV (live-attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV (live-attenuated Japanese encephalitis chimeric virus vaccine)
Trial: 32476520
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and dexamethasone therapy with doses adjusted based on creatinine clearance (10 mg for moderate RI, CrCl 30-60 mL/min)
Trial: 32476520
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and dexamethasone therapy
Trial: 32477016
Drug: RADREMI dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RADREMI dosing (SRS doses of 18 Gy for 0-2 cm lesions, 14 Gy for 2.1-3 cm lesions, and 12 Gy for 3.1-4 cm lesions)
Trial: 32477016
Drug: RADREMI dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RADREMI dosing
Trial: 32478195
Drug: Exubera (EXU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exubera (EXU; insulin human [rDNA origin] Inhalation Powder)
Trial: 32478814
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg
Trial: 32478814
Drug: Nivolumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 0.5 mg/kg
Trial: 32479189
Drug: Pembrolizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab with weekly cisplatin-based chemoradiotherapy
Trial: 32479608
Drug: Artefenomel 200-mg
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 200-mg dose
Trial: 32479608
Drug: Artefenomel 300-mg
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 300-mg dose (predicted)
Trial: 32480059
Drug: LDL-C <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C < 100 mg/dL (70-99 mg/dL)
Trial: 32480059
Drug: LDL-C <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C < 70 mg/dL
Trial: 32482616
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual antiplatelet therapy (DAPT)
Trial: 32482616
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy after one-month DAPT
Trial: 32484435
Drug: Topical dithranol
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dithranol (anthralin)
Trial: 32484552
Drug: Suvorexant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (10 mg for 1 week, titrated to 20 mg for 2 weeks)
Trial: 32485203
Drug: Ketamine (esketamine)
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ketamine (esketamine) treatment for TRD
Trial: 32486385
Drug: BI 860585
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 860585 monotherapy (5-300 mg/day)
Trial: 32486385
Drug: BI 860585
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 860585 (40-220 mg/day) with 25 mg/day exemestane
Trial: 32486385
Drug: BI 860585
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 860585 (80-220 mg/day) with 60-80 mg/m2 paclitaxel
Trial: 32487218
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy and radiotherapy
Trial: 32487218
Drug: CTC patterns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC patterns following treatment
Trial: 32487542
Drug: Trifluridine/tipiracil 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil 35 mg/m²
Trial: 32487574
Drug: Chemotherapy (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (first-line or third-line)
Trial: 32487574
Drug: Questionnaires including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Questionnaires including EORTC-QLQ-C30, Decisional Conflict Scale, Control Preferences Scale, Quality-Quantity Questionnaire, treatment expectations, EORTC financial toxicity items, Work Ability Index, FACT-G items, Decisional Regret Scale
Trial: 32487642
Drug: CTC/ctDNA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC/ctDNA combination assay
Trial: 32488055
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment strategy (TTS) guided by ex vivo drug sensitivity/resistance profiling (DSRP) and targeted next-generation sequencing (tNGS)
Trial: 32488055
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment strategy (TTS)
Trial: 32488989
Drug: Sapanisertib 40
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 40 mg single dose
Trial: 32489718
Drug: Algorithm for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm for measuring problem prescription opioid use
Trial: 32489805
Drug: Antithrombotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatment
Trial: 32489805
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs (APD)
Trial: 32489805
Drug: Overall anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall anticoagulation therapy patterns
Trial: 32492069
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (injection frequency ≤4)
Trial: 32492069
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (injection frequency ≥5)
Trial: 32492942
Drug: Cilostazol SR
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol SR capsule (200-mg)
Trial: 32492942
Drug: DAPT alone
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT alone (clopidogrel and aspirin)
Trial: 32493206
Drug: Erenumab 140-mg
RxNorm normalized name: erenumab-aooe 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140-mg monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks
Trial: 32493448
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A supplementation (3000 UI/kg/die for 28 days)
Trial: 32496203
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control group (daily sham text messages)
Trial: 32496541
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from diagnosis to treatment (TDT) of 0 to 5 days
Trial: 32496541
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from diagnosis to treatment (TDT) of 6 to 10 days
Trial: 32496541
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from diagnosis to treatment (TDT) of 11 to 15 days
Trial: 32496541
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from diagnosis to treatment (TDT) of >15 days
Trial: 32496557
Drug: Near-infrared photoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near-infrared photoimmunotherapy (NIR-PIT) using RM1929/ASP1929 (anti-EGFR antibody plus IRDye700DX)
Trial: 32497409
Drug: Weekly prophylaxis
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly prophylaxis (WP)
Trial: 32497409
Drug: Modified prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified prophylaxis or episodic treatment
Trial: 32497440
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI, Acthar® Gel) as adjunctive therapy along with DMARDs and glucocorticoids
Trial: 32497499
Drug: Single-cell RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-cell RNA and paired T cell receptor (TCR) sequencing
Trial: 32499275
Drug: Panenteric capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panenteric capsule endoscopy (CE)
Trial: 32499730
Drug: Theta-burst stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theta-burst stimulation (TBS) administered for 6 weeks (5 days a week for the first 3 weeks, then 2 days a week for the next 3 weeks) in the dorsolateral prefrontal cortex.
Trial: 32500620
Drug: Intra-articular autologous
RxNorm normalized name: autologous cultured chondrocytes 1.2e+007 INTRA-ARTICULAR IMPLANT [CARTICEL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular autologous bone marrow aspirate (BMA) injections
Trial: 32501454
Drug: High-dose anakinra
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose anakinra (5 mg/kg twice a day intravenously)
Trial: 32501454
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (200 mg hydroxychloroquine twice a day and 400 mg lopinavir with 100 mg ritonavir twice a day)
Trial: 32501528
Drug: Filanesib in
RxNorm normalized name: Filanesib
DrugBank: Filanesib (DB06040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filanesib in combination with pomalidomide and dexamethasone
Trial: 32502272
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 2 initial doses
Trial: 32502272
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 1 additional dose
Trial: 32502272
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 2 additional doses
Trial: 32502277
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25(OH)D <50 nmol/l)
Trial: 32502277
Drug: Severe vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe vitamin D deficiency (25(OH)D <25 nmol/l)
Trial: 32502506
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (Carboplatin/etoposide and cyclophosphamide/etoposide regimens, 4 cycles every 3 weeks) followed by radiation therapy (RT)
Trial: 32502506
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (18 Gy craniospinal RT for metastatic tumors, whole brain RT for basal ganglia tumors, or whole ventricular RT followed by 12.6 Gy boost RT)
Trial: 32503441
Drug: Baseline assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline assessment including self-administered PA and ST questionnaires and standardized measurement of blood pressure, waist circumference, and blood parameters; no treatment or intervention after 5 weeks
Trial: 32503469
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and entinostat (2 mg/m2)
Trial: 32503811
Drug: Medical compression
RxNorm normalized name: Truform Medical Compression Stockings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical compression therapy (classes I and II)
Trial: 32503866
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care - information leaflets and access to supervised exercise programmes, physical therapy, and healthy lifestyle programmes.
Trial: 32503947
Drug: murlentamab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: murlentamab treatment
Trial: 32503950
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and Ipilimumab combination therapy
Trial: 32506317
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily (BID), with adjustments to 10 mg BID permitted post-month 1.
Trial: 32506317
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID, with adjustments to 10 mg BID permitted post-month 1.
Trial: 32506428
Drug: Biological senescence
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological senescence group
Trial: 32506695
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with golimumab
Trial: 32507584
Drug: Increasing daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing daily volume of YCF consumed at age 24 months
Trial: 32508029
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg + gefitinib 250 mg (Cohort A)
Trial: 32508029
Drug: Apatinib 250
RxNorm normalized name: lapatinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250 mg + gefitinib 250 mg (Cohort B)
Trial: 32508541
Drug: Saline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (single bolus dose)
Trial: 32509978
Drug: Daily cow's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cow's milk intake >2 cups
Trial: 32510046
Drug: High load
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High load treatment